Bristol Myers Squibb stock holds steady as CAR T trial pause highlights risk and guidance

Bristol Myers Squibb stock is trading in the mid-60 USD range as investors weigh a precautionary pause of autoimmune CAR T trials against solid Q2 2026 earnings and a mid-teens valuation based on 2026 EPS guidance.

Bristol Myers Squibb stock (ISIN US0897961004) is trading around the mid-60 USD level as of August 30, 2026, with investors balancing solid Q2 2026 earnings guidance and valuation against the risk highlighted by a precautionary pause of autoimmune CAR T trials, according to recent market overviews dated August 30 and August 31, 2026.

CAR T trial pause sharpens risk focus

According to a report summarizing sector developments on September 1, 2026, Novartis and Bristol Myers Squibb have both paused multiple trials evaluating cell therapy programs for autoimmune conditions after inflammatory side effects were observed in testing, underscoring the safety sensitivity around next-generation CAR T therapies in new indications. A Stat News overview dated September 1, 2026 notes that the pauses are precautionary and linked to inflammatory side effects rather than a definitive efficacy failure, which means the long-term strategic potential of these programs remains but is now tied to clearer safety data.

Separate coverage of the cell therapy sector on September 1, 2026 indicates that Novartis temporarily halted certain autoimmune cell therapy studies after three fatal cases of a severe immune response, and that Bristol Myers Squibb also paused similar CAR T trials in autoimmune disorders as a precaution, highlighting how safety events at one player can trigger cross-checks across the field. A TimesLive article dated September 1, 2026 reports that Novartis responded to three fatal immune effector cell-associated syndromes by suspending programmes, and that Bristol Myers Squibb matched this cautious stance by pausing its own autoimmune CAR T work, which investors now see as a reminder that safety will be a gating factor for expanding cell therapies beyond oncology.

Valuation anchored by 2026 EPS guidance

A detailed market analysis on August 30 and August 31, 2026, focusing specifically on Bristol Myers Squibb stock, states that the latest reported fundamentals are the company’s Q2 2026 results, which currently frame investor expectations for execution in 2026. This overview notes that management has set fiscal 2026 EPS guidance in a range between 6.75 and 7.00 USD per share, giving the market a clear numeric framework for this year’s earnings power.

The same source highlights that consensus views compiled alongside management’s outlook center on an EPS projection of 6.95 USD for fiscal 2026, which is 0.20 USD above the lower end of the guidance range and 0.05 USD below the upper end, indicating that analysts broadly expect Bristol Myers Squibb to deliver performance in the upper half of its own 6.75 to 7.00 USD guidance band. With the stock trading at 66.47 USD as of August 30, 2026, this implies a price-to-earnings multiple in the mid-teens, positioning the valuation as consistent with a moderate-growth, cash-generative big pharma profile rather than a high-multiple speculative biotech, according to the same August 30, 2026 trading commentary.

Product focus on Eliquis

A factbox-style overview of drug pricing agreements with the U.S. government dated December of a prior year, but republished in a context article on September 1, 2026, recalls that Bristol Myers Squibb committed to providing its blockbuster blood-thinner Eliquis to Medicaid for free under certain arrangements, showing how the company’s cardiovascular franchise remains central to policy discussions. That factbox underscores that Eliquis continues to be a key revenue driver and a focal product when governments negotiate access and pricing for widely used therapies.

Stock price context and trading venue

Recent trading data summarized in an August 30, 2026 market snapshot show Bristol Myers Squibb stock on the New York Stock Exchange closing at 66.47 USD during the U.S. session on August 30, 2026, with an intraday range between 66.19 and 67.39 USD, indicating that the shares have been consolidating within a tight band in the mid-60 USD range rather than breaking out sharply. The same snapshot notes that subsequent commentary on August 31, 2026 referenced the shares near 66.58 USD, reinforcing that the stock has recently traded close to the mid-point of this band as investors digest both trial news and guidance.

Bristol Myers Squibb at a glance

• Company: Bristol Myers Squibb Company
• ISIN: US0897961004
• Ticker: BMY
• Trading venue: NYSE
• Price (as of August 30, 2026, 15:59): 66.47 USD
• Sector / Industry: Pharmaceuticals / Biotechnology
• Index membership: S&P 500